anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a water-repellent finished pigment which does not irritate the skin, has a moisture effect, is smooth and can be well spread, by treating the surface of a pigment or an extender pigment with hydrogenated lecithin. CONSTITUTION:The surface of a pigment or an extender pigement is treated or uniformly coated with hydrogenated lecithin. Examples of hydrogenated lecithin are those having an iodine value of 30 or below obtd. by hydrogenating synthetic lecithin or natural lecithin extracted from egg yolk, soybean, corn or rapeseed. The starting lecithin to be hydroganated must be chosen from those which are of high quality and neither oxidized nor discolored. The hydrogenated lecithin is completely adsorbed by the surface of the pigment in such a manner that 0.1-2 equivalents of a 1-30% aq. soln. of a soluble salt such as Al, Mg, Ca, Zn, Zr or Ti is added to the hydrogenated lecithin, whereby an insoluble metal salt of the hydrogenated lecithin is formed and completely adsorbed by the surface of the pigment.
The extract of Castanopsis cuspidata is provided to remove ROS(reactive oxygen species), protect cells by inhibiting cell death induced by hydrogen peroxide, promote activities of catalase, ERK(extracellular signal-regulated protein kinase) and NK(natural killer)-kappaB, and improve tissue damage by ROS, so that the extract is useful for treatment of inflammation, aging, cancer, arteriosclerosis and diabetes, and for aging improvement and skin inflammation alleviation. A composition for protecting cells from oxidative cell death comprises 0.01-10 wt.% of the extract of Castanopsis cuspidata var. sieboldii which is prepared by drying and pulverizing the stem of Castanopsis cuspidata var. sieboldii, extracting the pulverized Castanopsis cuspidata var. sieboldii with solvent selected from water, methanol, ethanol, or a mixed solvent thereof, and concentrating the extract under reduced pressure, and is formulated as injection, powder, granule, capsule, tablet, solution, cream, ointment or lotion. Further, the extract is extracted from a stem of the Castanopsis cuspidata var. sieboldii.
The intervention period lasted 6 months. At the baseline visit all AD subjects received information on the Atlantic diet and how to follow it; the nutritionists' messages were adapted to the clinical condition of each subject, his/her preferences, needs, beliefs and culture. Special care was taken with patients who were obese, had diabetes or who had high blood cholesterol; conflicts with recommendations made by subjects' own doctors or nutritionists were avoided. All questionnaires (see below) were filled out in the presence of the nutritionists, except for 3-day food records which the subjects handed in completed. The latter were reviewed in the presence of the subjects in order to correct any errors or add missing information. At the 3 and 6 month visits, the nutritionists reminded the subjects about the Atlantic diet and the helped them complete their questionnaires.

Foods were provided to the families of the AD group. Wine was provided only to non-tee-total adults. Food packages were delivered every three weeks to the family home. The food included in the package was calculated for the total number of family members, even if not all were taking part in the study. At delivery, a form was filled in to verify that the previous lot of food had been consumed, and to note any problems.
<P>PROBLEM TO BE SOLVED: To provide a method for introducing a drug by which the drug can selectively be introduced into a specific cell with an inexpensive apparatus and to provide the apparatus for introducing the drug.  <P>SOLUTION: The drug such as a therapeutic gene is injected into a biological tissue with a syringe to localize the drug near the cell into which the drug is to be introduced. A pigment (e.g. hemoglobin) as a target near the cell is irradiated with laser beams at ≥100 ps pulse width to thereby introduce the drug into the cell. The laser pulse is selectively absorbed with the pigment (linear absorption) to induce a temperature rise and a pressure wave (a thermoelastic wave). Thereby, permeability into the cell membrane is increased.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
PURPOSE:To obtain an antiviral agent effective against virus infectious diseases, especially retrovirus infectious diseases, having low toxicity and excellent safety, containing a lectin extracted from Magnoliatae as an active ingredient. CONSTITUTION:Seed of a dicotyledon selected from Iotus tetragonolobus Ulex curopeus, Maakia amurensis, Glycine max. Canavalia ensiformis or Lens culinaris is extracted with an aqueous solvent and purified to give a lectin, hemagglutinin. The lectin as an active ingredient is pharmaceutically manufactured by conventional procedure to give the aimed substance. A daily dose is 0.1-1,000mg, 1-100mg per kg weight in the case of oral administration and administered once-three times dividedly. The lectin has the following properties. Positive in naphthol-sulfuric acid reaction, indole-sulfuric acid reaction, anthrone-sulfuric acid reaction and ninhydrin reaction. Elemental analytical values. C 20-55%, H 3-9%, N 0.1-16.0%. pH6.0-7.5. Soluble in organic solvents. 10<3>-3X10<6>mol.wt.
Teeth with reversible pulpitis according to the inclusion criteria (see below) will be included. Depending on the clinical situation, a partial or full pulpotomy will be conducted accordingly to the defined clinical protocols (see below). In this study arm, we want to evaluate 1) different times of pulpal bleeding before pulp capping and 2) partial versus full pulpotomy on the clinical outcome in teeth with irreversible pulpitis.
The first three subjects will squirt via syringe into their mouths (po) 4.2 mg (2.1ml) mg of reconstituted (with 5 ml of 0.9% saline) QRH-882260 heptapeptide (\~100 µM concentration). They will be asked to wait 5 minutes and then drink at least 4-8oz of tap water. The remaining seven subjects will receive (squirted via syringe into their mouths) 1mg (5ml) of reconstituted (with 5ml of 0.9% saline) QRH-882260 heptapeptide (\~100 µM concentration).
Fentanyl transdermal system contains fentanyl, an opioid agonist and a Schedule II controlled substance with an abuse liability similar to other opioid analgesics. Schedule II opioid substances which include hydromorphone, morphine, oxycodone, fentanyl, oxymorphone and methadone have the highest potential for abuse and risk of fatal overdose due to respiratory depression. Fentanyl transdermal system can be abused in a manner similar to other opioid agonists, legal or illicit. These risks should be considered when administering, prescribing, or dispensing fentanyl transdermal system in situations where the healthcare professional is concerned about increased risk of misuse, abuse, or diversion [see Drug Abuse and Dependence (9)].

Assess patients for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. Routinely monitor all patients receiving opioids for signs of misuse, abuse and addiction since use of opioid analgesic products carries the risk of addiction even under appropriate medical use. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (i.e., major depression). Patients at increased risk may still be appropriately treated with modified-release opioid formulations; however these patients will require intensive monitoring for signs of misuse, abuse, or addiction. Concerns about abuse, addiction, and diversion should not prevent the proper management of pain.

Contact local state professional licensing board or state controlled substances authority for information on how to prevent and detect abuse or diversion of this product.
The invention relates to pharmaceutical preparations providing delayed release of an active substance, whereby said active substance is contained in or on pellets. The invention is characterized in that the pellets are coated with a diffusion membrane which is permeable with respect to said active substance but delays the diffusion thereof. The coating is made up of talc and poleythacrylate-polymethylacrylate. Mesopram is used as an active substance. The inventive preparation provides a constant plasma level in vivo without any peaks. The medicaments produced from the pharmaceutical preparation exhibit active substance release independent of pH and have high stability in storage.
OBJECTIVE: To compare two surgical techniques, the Wendler glottoplasty (GP) and its modification, the vocal fold shortening, and retrodisplacement of the anterior commissure (VFSRAC) associated with laser assisted voice adjustment (LAVA) cordotomy, used to feminize the voice of transgender women by increasing the fundamental frequency (F0).
METHODS: A retrospective study of 22 trans-women (20-62 years-old) was carried out. 12 of them were treated with GP and 10 with the VFSRAC+LAVA technique. They were evaluated before surgery and 6 months after surgery and the postoperative speech therapy. Laryngostroboscopy examination, F0 measurements, Transgender Woman Voice Questionnaire (TWVQ) assessment and the perceptual assessment using a visual analog scale (PA-VAS) were obtained from all patients.
RESULTS: Laryngostroboscopic findings showed normal vocal folds before surgery and a shortening of the vocal folds, due to the anterior glottic synechia, after surgery. Significant increases of F0 were found in both groups but they were higher in the VFSRAC+LAVA group (47.75Hz in GP group vs 69.70Hz in VFSRAC+LAVA group). TWVQ scores showed a significant decrease in both groups although the difference was greater in the VFSRAC+LAVA group. Similarly, PA-VAS scores lowered significantly in both groups but VFSRAC+LAVA group presented the biggest decreases.
CONCLUSION: Both surgical techniques produce the shortening of the vocal folds through an endoscopic approach and result in voices with higher vocal pitch. Of the two techniques presented, the VFSRAC+LAVA produces better results although when compared with previous studies it seems that the LAVA technique may not significantly contribute to the postoperative results. So, the VFSRAC technique followed by postoperative speech therapy could be recommended for trans-women who wish to feminize their voice.
Patients undergo observation for 16 weeks. At week 16, patients undergo biopsy. Patients with persistent HGPIN by biopsy receive 2 courses of calcitriol as in arm I.
The PF condition will consist of a 90-minute parent group session twice per week. The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent.
The invention relates to a procationic/ cationic liposome curcumin preparation for interventional treatment of hepatic carcinoma and a preparation method of the preparation. The preparation consists of curcumin and multiple components which can be pharmaceutically prepared into a procationic/ cationic liposome carrier. The preparation is mainly prepared from the following raw materials in percentage by weight: 0.001 to 5 percent of curcumin, and 95 to 99.999 percent of procationic/ cationic liposome carrier. The cationic liposome curcumin preparation is prepared from egg yolk lecithin, cholesterol, octadecyl amine, vitamin E, ether, anhydrous ethanol, curcumin and the like by adopting a film dispersion method. The procationic liposome curcumin preparation is prepared from egg yolk lecithin, cholesterol, [2-[[4-[(carboxymethyl) dithio]-1-imidobutyl] amino] ethyl] carbamic acid cholesteryl ester (CHETA), vitamin E, ether, anhydrous ethanol, curcumin and the like by adopting the film dispersion method. The preparation for the interventional treatment of the hepatic carcinoma is efficient and safe.
The rat repellent system includes a structural member saturated with a menthol solution. The structural member is a fibrous member, such that saturation may be accomplished by submerging the structural member into the menthol solution to allow the structural member to absorb the menthol solution. To maximize saturation, the submerged structural member may be pressurized. The structural member is configured to releasably couple to a substrate, such as a wall stud, a floor joist, a structural beam, or a shipping pallet. The structural member couples to the substrate using a fastener, such as a nail, a screw, or a bolt that passes through an aperture in the structural member and into the substrate. The structural member may also be coupled to a substrate using a clamp.
Mild Cognitive Impairment in a single or a multiple domain (Jak et al., 2009) with AD symptoms (MCI-AD; Dubois, B., et al. 2009. Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin Neurosci. 11(2): 135-9.).
A system and method for determining an Ayurvedic body type of a user is disclosed. The Ayurvedic body type is determined by presenting the user with a questionnaire. A weighted average score is calculated corresponding to each of Vata, Pitta and Kapha based on response of user to questionnaire, an image of user, voice sample of the user and vital signs of the user. Further, the weighted average score is compared against predefined thresholds to determine the Ayurvedic body type. The imbalances in natural body composition of the user is determined based on the response of the user to the questionnaire, the image of the user, the voice sample of the user and the vital signs of the user. Recommendations are provided to restore the balance in the body composition.
Using the materials developed during study year one, up to nine approximately 60-90 minute sessions will be carried out with groups of 8-10 participants at a time randomized to receive ESS-HSU. Each by session will be administered by two facilitators and will be carried out over a virtual platform (e.g., Zoom, Teams). Any session hand-outs will be mailed and/or emailed to participants prior to each session and shared onscreen. Participants in the ESS-HSU condition may also receive study-provided tablet computers with data plans to facilitate their engagement in the intervention (as needed).
BACKGROUND AND PURPOSE: Spontaneous intracranial hypotension (SIH) is caused by spinal cerebrospinal fluid (CSF) leaks. This study assessed whether the certainty and/or multifocality of CSF leaks is associated with the severity of intracranial sequelae of SIH.
MATERIALS AND METHODS: A retrospective review was completed of patients with suspected SIH that underwent digital subtraction myelogram (DSM) preceded by brain MRI. DSMs were evaluated for the presence or absence of a CSF leak, categorized both as positive/negative/indeterminate and single versus multifocal. Brain MRIs were assessed for intracranial sequelae of SIH based on two probabilistic scoring systems (Dobrocky and Mayo methods). For each system, both an absolute "numerical" score (based on tabulation of findings) and "categorized" score (classification of probability) were tabulated.
RESULTS: 174 patients were included; 113 (64.9%) were female, average age 52.0 ± 14.3 years. One or more definite leaks were noted in 76 (43.7%) patients; an indeterminate leak was noted in 22 (12.6%) patients. 16 (16.3%) had multiple leaks. There was no significant difference in the severity of intracranial findings between patients with a single versus multiple leaks (p values ranged from .36 to .70 using categorized scores and 0.22-0.99 for numerical scores). Definite leaks were more likely to have both higher categorized intracranial scores (Mayo p = .0008, Dobrocky p = .006) and numerical scores (p = .0002 for Mayo and p = .006 for Dobrocky).
CONCLUSIONS: Certainty of a CSF leak on diagnostic imaging is associated with severity of intracranial sequelae of SIH, with definite leaks having significantly more intracranial findings than indeterminate leaks. Multifocal leaks do not cause greater intracranial abnormalities.
The invention discloses application of Fructus Trichosanthis alcohol extract in preparation of drugs or health products for preventing and treating bladder cancer. Experiments indicate that Fructus Trichosanthis alcohol extract is effective for regulating and controlling tumor growth related genes and inhibiting the growth of tumor cells. In a nude mouse body, the Fructus Trichosanthis alcohol extract is effective for inhibiting the growth of transplantation tumors in nude mice with bladder cancer cells. The toxic and side effects of chemotherapeutic drugs can be decreased, and a novel target drug is provided for the clinical treatment against the growth of bladder cancer stem/progenitor cells. Fructus Trichosanthis has low price and convenient to obtain. It is expected to use Fructus Trichosanthis alcohol extract as an effective ingredient to prepare drugs or health products for preventing and treating bladder cancer.
BACKGROUND: Bilateral optic neuritis associated with optic disc swelling is a common feature of myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). However, extensive deep retinal haemorrhages have not been described in the context of MOG-associated optic neuritis. Here, we report a case of infectious mononucleosis with marked binocular peripapillary and perivascular haemorrhages as well as extensive deep retinal haemorrhages in the presence of MOGAD.
CASE REPORT: A 39-year-old Chinese woman presenting with subacute binocular vision reduction with no light perception was diagnosed with MOGAD. Fundus examination revealed the presence of binocular peripapillary and perivascular haemorrhages as well as extensive deep retinal haemorrhages with severe optic disc swelling greater in the right eye than in the left and dilated and tortuous retinal venules. The patient tested positive for the Epstein-Barr virus (EBV) antigen (595 U/mL) and the EBV capsid antigen (>750 U/mL). She had a fever and right upper quadrant abdominal pain, and a doctor determined splenomegaly 1 week before the onset of orbital pain and decreased vision acuity. Medical history and laboratory tests indicated the presence of concurrent infectious mononucleosis. Other investigational indicators of retinal haemorrhages, including hypertension, diabetes mellitus, vascular disease, systemic lupus erythematosus, metabolic disease, and renal or liver dysfunction, were absent.
DISCUSSION: This case suggests that retinal haemorrhage is a possible complication of infectious mononucleosis in the presence of MOGAD.
A kind of piperphentonamine hydrochloride lyophilized powder for injection and a preparation method thereof. The injection is prepared by one portion of piperphentonamine hydrochloride, 2.5-30 parts of excipient and 400-600 parts of water for injection with pH 1.5-5.5 via freeze-drying. The excipient is mannitol, dextran, lactose, saccharose, polyethylene glycol, poloxamer, glycine, etc.; It is preferred that the injection comprises one part of piperphentonamine hydrochloride, 10 parts of mannitol and 500 parts of water for injection with pH 2.0-3.0. The product is prepared by adding said piperphentonamine hydrochloride and excipient into water for injection, heating at 40° C.-90° C., ultrasonic dissolving, degerming, individually packing, pre-freezing and multistage drying, and packaging. Individually packing into a tubular glass bottle with brown color is preferred. The appearance, color & luster and solubility of the injection are excellent, the stability is good and with long storage period. The invention also provides the uses of the injection in the preparation of a medicament for treatment of heart failure and/or cardioprotection.
The present invention relates to a viral vector capable of the transfer and in vivo expression of growth-associated protein (B-50/GAP-43) in neuronal target cells of a mammalian host. The viral vector contains a recombinant DNA molecule comprising a B-50/GAP-43 gene operably associated with a promoter, which promoter controls short term, high level expression of the B-50/GAP-43 gene. Preferably, the viral vector is a defective viral vector, in particular a defective herpes virus or an adeno-associated virus. In a specific embodiment, defective herpesvirus, adenovirus, and adeno-associated virus viral vectors containing the rat B-50/GAP-43 gene under control of the human cytomegalovirus immediate early promoter have been prepared. The invention further provides a method for treating nerve damage in a subject. The method comprises introducing a vector comprising a B-50/GAP-43 gene operably associated with a promoter into a damaged nerve tissue of a subject. Preferably, the promoter controls short term, high level expression of the B-50/GAP-43 gene, such that the B-50/GAP-43 gene is expressed in the tissue of the subject. Preferably, the vector used in the therapeutic methods of the invention is a viral vector. The vectors of the invention, capable of expression a B-50/GAP-43 gene, can also be used in vitro to enhance the survival of cultured cells, in particular, cultured neurons for transplantation.
Type 1 diabetes remains the most common chronic disease of childhood and affects millions of children and adults globally. The minority of persons with type 1 diabetes achieve the recommended glycemic targets. Currently approved and unapproved automated insulin delivery systems require patients to carry and wear multiple devices (pumps, tubing, blood glucose meters, mobile devices, etc.). There is a need to design automated insulin delivery systems that reduce the burden of diabetes management for young persons and their families in an effort to improve glycemic control as well as other biomedical and psychosocial outcomes.

The purpose of this study is to conduct separate semi-structured interviews with young persons with type 1 diabetes and parents of youth with type 1 diabetes (not necessarily the parents of the youth participants) regarding their preferences for an automated, on-body insulin delivery system. Youth and parents will also complete short surveys related to perceived burden of diabetes self-care, quality of life, acceptance of diabetes, and worries about hypoglycemia. The feedback received from the interviews and surveys will help inform the design of a new on-body automated insulin delivery system.
Patients 18-75 year old with refractory ascites or hepatic hydrothorax and cirrhosis, eligible for TIPS placement. All patients will have a baseline oral glutamine challenge and psychometric tests.
Cefepime 50 mg/kg per dose (up to 2 g/dose) will be dministered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefepime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
PURPOSE:To prepare a physiologically active substance useful for the preparation of pharmaceuticals, in high yield, keeping the proliferation degree of cells even in a long-term subculture on an industrial scale, by culturing human-originated cell in a medium added with human plasma of type AB. CONSTITUTION:The objective physiologically active substance can be prepared by culturing human-originated cells in a medium added with human plasma of type AB. The human plasma is preferably inactivated at 50-60 deg.C for 10-60min before addition, and its amount is preferably 10-20V/V% based on the medium. Addition of the human plasma of type AB enables the culture of human-originated cells on an industrial scale. The cell is especially lymphoblastoid cell producing monoclonal anti-HBs antibody and obtained by the transformation of a human lymphocyte B acpable of producing HBs antibody, with Epstein's pearl virus. It can be utilized for the production of monoclonal anti-HBs antibody, urokinase, etc.